Episode: Salgia Summarizes the Benefits of Tepotinib in MET Exon 14–Mutated NSCLC
Description: Dr Salgia discusses how he chooses between tepotinib and capmatinib in patients with stage IV NSCLC harboring MET exon 14 skipping mutations.
Click any word to see translations, usage examples & similar words. Then learn them using saved words.
Text not synced with the audio? See here for why certain podcasts won't sync.
